Which has better valuation and earnings, LQDA or PLSE?

Liquidia has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 44.90 -$68.92M $0.14 571.00 Pulse Biosciences $751K 2,643.07 -$72.78M -$1.10 N/A

Does the media prefer LQDA or PLSE?

In the previous week, Liquidia had 32 more articles in the media than Pulse Biosciences. MarketBeat recorded 33 mentions for Liquidia and 1 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.23 beat Liquidia's score of 0.37 indicating that Pulse Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 14 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pulse Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PLSE or STVN?

Pulse Biosciences currently has a consensus price target of $30.67, suggesting a potential upside of 6.93%. Given Pulse Biosciences' higher possible upside, equities analysts clearly believe Pulse Biosciences is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulse Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00

Does the media prefer PLSE or STVN?

In the previous week, Stevanato Group had 2 more articles in the media than Pulse Biosciences. MarketBeat recorded 3 mentions for Stevanato Group and 1 mentions for Pulse Biosciences. Stevanato Group's average media sentiment score of 1.73 beat Pulse Biosciences' score of 1.23 indicating that Stevanato Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stevanato Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to BLCO or PLSE?

In the previous week, Bausch + Lomb and Bausch + Lomb both had 1 articles in the media. Pulse Biosciences' average media sentiment score of 1.23 beat Bausch + Lomb's score of 0.44 indicating that Pulse Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pulse Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LIVN or PLSE?

In the previous week, LivaNova had 1 more articles in the media than Pulse Biosciences. MarketBeat recorded 2 mentions for LivaNova and 1 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.23 beat LivaNova's score of 1.01 indicating that Pulse Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulse Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PLSE or NVST?

In the previous week, Pulse Biosciences and Pulse Biosciences both had 1 articles in the media. Pulse Biosciences' average media sentiment score of 1.23 beat Envista's score of 0.90 indicating that Pulse Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Envista 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pulse Biosciences (PLSE) Competitors

$28.68 +1.30 (+4.75%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$28.72 +0.05 (+0.16%)

As of 07/17/2026 07:27 PM Eastern

Compare

PLSE vs. LQDA, STVN, BLCO, LIVN, and NVST

Should you buy Pulse Biosciences stock or one of its competitors? MarketBeat compares Pulse Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pulse Biosciences include Liquidia (LQDA), Stevanato Group (STVN), Bausch + Lomb (BLCO), LivaNova (LIVN), and Envista (NVST). These companies are all part of the "medical equipment" industry.

How does Pulse Biosciences compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Pulse Biosciences (NASDAQ:PLSE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Liquidia has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	44.90	-$68.92M	$0.14	571.00
Pulse Biosciences	$751K	2,643.07	-$72.78M	-$1.10	N/A

Liquidia has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

Liquidia has a net margin of 7.74% compared to Pulse Biosciences' net margin of 0.00%. Liquidia's return on equity of 46.82% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
Pulse Biosciences	N/A	-86.67%	-73.61%

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 76.9% of Pulse Biosciences shares are owned by institutional investors. 25.6% of Liquidia shares are owned by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Liquidia had 32 more articles in the media than Pulse Biosciences. MarketBeat recorded 33 mentions for Liquidia and 1 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.23 beat Liquidia's score of 0.37 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	14 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulse Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Liquidia presently has a consensus target price of $68.88, suggesting a potential downside of 13.84%. Pulse Biosciences has a consensus target price of $30.67, suggesting a potential upside of 6.93%. Given Pulse Biosciences' higher possible upside, analysts plainly believe Pulse Biosciences is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Liquidia beats Pulse Biosciences on 11 of the 17 factors compared between the two stocks.

How does Pulse Biosciences compare to Stevanato Group?

Pulse Biosciences (NASDAQ:PLSE) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

Stevanato Group has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$751K	2,643.07	-$72.78M	-$1.10	N/A
Stevanato Group	€1.34B	4.34	€158.21M	€0.59	32.57

Pulse Biosciences has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

In the previous week, Stevanato Group had 2 more articles in the media than Pulse Biosciences. MarketBeat recorded 3 mentions for Stevanato Group and 1 mentions for Pulse Biosciences. Stevanato Group's average media sentiment score of 1.73 beat Pulse Biosciences' score of 1.23 indicating that Stevanato Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

76.9% of Pulse Biosciences shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 0.7% of Stevanato Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pulse Biosciences currently has a consensus price target of $30.67, suggesting a potential upside of 6.93%. Given Pulse Biosciences' higher possible upside, equities analysts clearly believe Pulse Biosciences is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Stevanato Group has a net margin of 11.76% compared to Pulse Biosciences' net margin of 0.00%. Stevanato Group's return on equity of 10.27% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
Stevanato Group	11.76%	10.27%	6.08%

Summary

Stevanato Group beats Pulse Biosciences on 11 of the 17 factors compared between the two stocks.

How does Pulse Biosciences compare to Bausch + Lomb?

Bausch + Lomb (NYSE:BLCO) and Pulse Biosciences (NASDAQ:PLSE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 76.9% of Pulse Biosciences shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pulse Biosciences has a net margin of 0.00% compared to Bausch + Lomb's net margin of -4.21%. Bausch + Lomb's return on equity of 3.60% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
Pulse Biosciences	N/A	-86.67%	-73.61%

Bausch + Lomb has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

In the previous week, Bausch + Lomb and Bausch + Lomb both had 1 articles in the media. Pulse Biosciences' average media sentiment score of 1.23 beat Bausch + Lomb's score of 0.44 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulse Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pulse Biosciences has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.14	-$360M	-$0.62	N/A
Pulse Biosciences	$751K	2,643.07	-$72.78M	-$1.10	N/A

Bausch + Lomb presently has a consensus target price of $18.00, indicating a potential upside of 10.70%. Pulse Biosciences has a consensus target price of $30.67, indicating a potential upside of 6.93%. Given Bausch + Lomb's higher probable upside, analysts clearly believe Bausch + Lomb is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Pulse Biosciences beats Bausch + Lomb on 9 of the 15 factors compared between the two stocks.

How does Pulse Biosciences compare to LivaNova?

LivaNova (NASDAQ:LIVN) and Pulse Biosciences (NASDAQ:PLSE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

In the previous week, LivaNova had 1 more articles in the media than Pulse Biosciences. MarketBeat recorded 2 mentions for LivaNova and 1 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.23 beat LivaNova's score of 1.01 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulse Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LivaNova has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

LivaNova has a net margin of 7.48% compared to Pulse Biosciences' net margin of 0.00%. LivaNova's return on equity of 16.48% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Pulse Biosciences	N/A	-86.67%	-73.61%

Pulse Biosciences has lower revenue, but higher earnings than LivaNova. Pulse Biosciences is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.19	-$242.47M	$1.95	41.38
Pulse Biosciences	$751K	2,643.07	-$72.78M	-$1.10	N/A

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 76.9% of Pulse Biosciences shares are owned by institutional investors. 0.4% of LivaNova shares are owned by insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

LivaNova currently has a consensus target price of $81.38, suggesting a potential upside of 0.84%. Pulse Biosciences has a consensus target price of $30.67, suggesting a potential upside of 6.93%. Given Pulse Biosciences' higher possible upside, analysts clearly believe Pulse Biosciences is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

LivaNova beats Pulse Biosciences on 10 of the 16 factors compared between the two stocks.

How does Pulse Biosciences compare to Envista?

Pulse Biosciences (NASDAQ:PLSE) and Envista (NYSE:NVST) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Pulse Biosciences currently has a consensus target price of $30.67, suggesting a potential upside of 6.93%. Envista has a consensus target price of $28.54, suggesting a potential upside of 6.79%. Given Pulse Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Pulse Biosciences is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Envista	0 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

Pulse Biosciences has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market. Comparatively, Envista has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

Envista has a net margin of 2.41% compared to Pulse Biosciences' net margin of 0.00%. Envista's return on equity of 7.11% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
Envista	2.41%	7.11%	3.91%

In the previous week, Pulse Biosciences and Pulse Biosciences both had 1 articles in the media. Pulse Biosciences' average media sentiment score of 1.23 beat Envista's score of 0.90 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Envista	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

76.9% of Pulse Biosciences shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Comparatively, 1.0% of Envista shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Envista has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$751K	2,643.07	-$72.78M	-$1.10	N/A
Envista	$2.72B	1.60	$47M	$0.41	65.18

Summary

Envista beats Pulse Biosciences on 8 of the 15 factors compared between the two stocks.

Get Pulse Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLSE vs. The Competition

Export

Metric	Pulse Biosciences	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.89B	$7.63B	$6.88B	$12.40B
Dividend Yield	N/A	1.32%	2.67%	8.85%
P/E Ratio	-26.07	50.09	27.17	23.92
Price / Sales	2,643.07	49.29	529.41	91.77
Price / Cash	N/A	26.87	51.46	60.07
Price / Book	24.10	7.03	10.69	6.18
Net Income	-$72.78M	$162.30M	$3.59B	$332.18M
7 Day Performance	9.09%	-2.22%	-2.19%	-2.06%
1 Month Performance	12.03%	-1.20%	1.64%	-2.15%
1 Year Performance	89.93%	6.83%	25.60%	17.26%

Pulse Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLSE Pulse Biosciences	1.9678 of 5 stars	$28.68 +4.7%	$30.67 +6.9%	+83.3%	$1.89B	$751K	N/A	140	Positive News Gap Down
LQDA Liquidia	2.6303 of 5 stars	$76.49 +7.4%	$68.88 -10.0%	+447.5%	$6.33B	$158.32M	546.40	50	Insider Trade
STVN Stevanato Group	3.0488 of 5 stars	€19.88 +0.3%	N/A	-24.7%	€6.02B	€1.34B	33.69	6,010	News Coverage Analyst Upgrade
BLCO Bausch + Lomb	3.5171 of 5 stars	$15.96 -1.6%	$18.00 +12.8%	+14.6%	$5.79B	$5.10B	N/A	13,000
LIVN LivaNova	1.7793 of 5 stars	$79.12 -4.7%	$80.75 +2.1%	+89.7%	$4.56B	$1.39B	40.57	3,300	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLSE) was last updated on 7/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulse Biosciences (PLSE) Competitors

PLSE vs. LQDA, STVN, BLCO, LIVN, and NVST

How does Pulse Biosciences compare to Liquidia?

Summary

How does Pulse Biosciences compare to Stevanato Group?

Summary

How does Pulse Biosciences compare to Bausch + Lomb?

Summary

How does Pulse Biosciences compare to LivaNova?

Summary

How does Pulse Biosciences compare to Envista?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLSE vs. The Competition

Pulse Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulse Biosciences (PLSE) Competitors

PLSE vs. LQDA, STVN, BLCO, LIVN, and NVST

How does Pulse Biosciences compare to Liquidia?

Which has better valuation and earnings, LQDA or PLSE?

Which has more volatility & risk, LQDA or PLSE?

Is LQDA or PLSE more profitable?

Do insiders and institutionals have more ownership in LQDA or PLSE?

Does the media prefer LQDA or PLSE?

Do analysts prefer LQDA or PLSE?

Summary

How does Pulse Biosciences compare to Stevanato Group?

Which has preferable earnings & valuation, PLSE or STVN?

Which has more risk and volatility, PLSE or STVN?

Does the media prefer PLSE or STVN?

Do insiders & institutionals hold more shares of PLSE or STVN?

Do analysts rate PLSE or STVN?

Is PLSE or STVN more profitable?

Summary

How does Pulse Biosciences compare to Bausch + Lomb?

Do insiders & institutionals have more ownership in BLCO or PLSE?

Is BLCO or PLSE more profitable?

Which has more risk and volatility, BLCO or PLSE?

Does the media refer more to BLCO or PLSE?

Which has higher earnings & valuation, BLCO or PLSE?

Do analysts recommend BLCO or PLSE?

Summary

How does Pulse Biosciences compare to LivaNova?

Does the media refer more to LIVN or PLSE?

Which has more volatility and risk, LIVN or PLSE?

Is LIVN or PLSE more profitable?

Which has stronger earnings & valuation, LIVN or PLSE?

Do institutionals & insiders hold more shares of LIVN or PLSE?

Do analysts prefer LIVN or PLSE?

Summary

How does Pulse Biosciences compare to Envista?

Do analysts recommend PLSE or NVST?

Which has more volatility & risk, PLSE or NVST?

Is PLSE or NVST more profitable?

Does the media prefer PLSE or NVST?

Do insiders & institutionals hold more shares of PLSE or NVST?

Which has better valuation & earnings, PLSE or NVST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLSE vs. The Competition

Pulse Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools